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Background. Vaccine-derived polioviruses (VDPVs) have caused poliomyelitis outbreaks in communities with sub-optimal
vaccination. Israeli environmental surveillance of sewage from populations with high (.95%) documented vaccine coverage of
confirmed efficacy identified two separate evolutionary clusters of VDPVs: Group 1 (1998–2005, one system, population
1.6610
6) and Group 2 (2006, 2 systems, populations 0.7610
6 and 5610
4). Principal Findings. Molecular analyses support
evolution of nine Group 1 VDPVs along five different lineages, starting from a common ancestral type 2 vaccine-derived Sabin-
2/Sabin-1 recombinant strain, and independent evolution of three Group 2 VDPVs along one lineage starting from a different
recombinant strain. The primary evidence for two independent origins was based on comparison of unique recombination
fingerprints, the number and distribution of identical substitutions, and evolutionary rates. Geometric mean titers of
neutralizing antibodies against Group 1 VDPVs were significantly lower than against vaccine strains in all age-group cohorts
tested. All individuals had neutralizing titers .1:8 against these VDPVs except 7% of the 20–50 year cohort. Group 1 VDPVs
were highly neurovirulent in a transgenic mouse model. Intermediate levels of protective immunity against Group 2 VDPVs
correlated with fewer (5.0+1.0) amino acid substitutions in neutralizing antigenic sites than in Group 1 VDPV’s (12.161.5).
Significance. VDPVs that revert from live oral attenuated vaccines and reacquire characteristics of wild-type polioviruses not
only threaten populations with poor immune coverage, but are also a potential source for re-introduction of poliomyelitis into
highly immune populations through older individuals with waning immunity. The presence of two independently evolved
groups of VDPVs in Israel and the growing number of reports of environmental VDPV elsewhere make it imperative to
determine the global frequency of environmental VDPV. Our study underscores the importance of the environmental
surveillance and the need to reconsider the global strategies for polio eradication and the proposed cessation of vaccination.
Citation: Shulman LM, Manor Y, Sofer D, Handsher R, Swartz T, et al (2006) Neurovirulent Vaccine-Derived Polioviruses in Sewage from Highly
Immune Populations. PLoS ONE 1(1): e69. doi:10.1371/journal.pone.0000069
INTRODUCTION
Enhanced inactivated polio vaccine (eIPV) is an enhanced potency
injectable trivalent vaccine produced from wild-type poliovirus
strains representing each of the three poliovirus serotypes [1]. The
polioviruses in eIPV have been inactivated with formalin. In
contrast, OPV is a trivalent attenuated live virus vaccine where the
poliovirus of each serotype was derived by selecting progeny of
wild poliovirus that had lost their neurovirulence. Between 1990
and 2005, infants in Israel received three doses of eIPV and three
doses of OPV poliovirus vaccines by the age of 15 months [2],
followed by an OPV booster in first grade (age five to six). After
2005, the routine immunization schedule was changed and
consisted of 4 eIPV by 15 months and an eIPV booster in first
grade. From 1999, national vaccination coverage ranged between
92% and 95% and within individual health districts from 81 to
100%. Annual sero-surveys documented .95% immunity to all
three strains consistent with previous reports [2]. The Palestinian
Health Authority and/or UNRWA administered a similar com-
bined OPV/eIPV vaccination program to all children in the West
Bank and Gaza districts supplemented with bi-annual National
Immunization Days for children 0 to 5 years old. As a consequence
both Israel and the Palestinian territories have been free of
poliomyelitis in the last decade [3,4].
All three poliovirus serotypes have high mutation rates [5,6].
Polioviruses of all three serotypes in Sabin live tri-valent OPV, like
all other polioviruses, readily accumulate mutations during passage
in human hosts. Nucleotide misincorporation into the viral genome
occurs at a fairly constant rate [3,7]. This rate can be used as a
rough ‘‘molecular clock’’ to estimate evolutionary intervals between
isolates [3,8]. Some vaccine progeny revert to wild phenotype (as
only 2 to 3 nucleotide substitutions differentiate between the two
phenotypes) [9] and this reversion to neurovirulence may even
occur during infection of the primary vaccinee [10]. Circulating
polioviruses also frequently recombine with genomes of other polio
and non-polio enteroviruses in primary or subsequent hosts [11–
14]. Recombination junctions generally clustered in particular
subgenomic regions that were dependent on the serotype of the
isolate and/or on the associations of genomic segments in
recombinants[15]. However, since these preferential recombina-
tion sites are not very precise hot spots, it is broadly accepted that
shared recombinations imply common ancestry.
A poliovirus isolate is classified as vaccine, vaccine-derived
(VDPV), or wild type poliovirus based on the percent nucleotide
sequence homology between its capsid protein VP1 and that of the
corresponding OPV vaccine serotype. VP1 homology of 99–100%
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wild type poliovirus [16]. VDPVs evolve from vaccine along one of
two known pathways indicated by the letter ‘‘i’’ or ‘‘c’’ preceding
the word ‘‘VDPV’’. VDPVs that arise during persistent infection
of immunodeficient individuals are termed iVDPV [17]. VDPVs
that evolve during continuous transmissions of vaccine virus
between unvaccinated individuals in populations with low
vaccination coverage [17–19] or when vaccination programs are
interrupted and sufficient numbers of unimmunized infants
accumulate [20] are termed ‘‘circulating VDPV’’ (cVDPV).
In recent years vaccine-derived poliovirus (cVDPVs) have
caused poliomyelitis outbreaks in developing countries with low
immunization coverage [18]. In general, unvaccinated sub-
populations are protected by herd immunity when vaccination
rates are sufficiently high [21]. However, there are exceptions, the
most recent being circulation of VDPV in the Amish community
in Minnesota, USA [22].
The aim of monthly surveillance of sewage from sentinel
communities initiated in Israel in 1989 is to monitor circulation of
poliovirus in the absence of poliomyelitis, to characterize the
polioviruses that circulate and to asses the risk for reemergence of
poliomyelitis [4,23]. The sensitivity of environmental surveillance
depends on many factors such as population size, sample frequency
and physical properties of the sewage system [24]. Each sewage
isolate wascharacterized as OPV, VDPV,orwild type byserological
and molecular methods [16]. Extensive molecular analysis of each
VDPV isolate is a requirement to determine whether it arose as
a cVDPV or iVDPV. Distinction between circulating virus and virus
excreted by one or at most a few individuals, is obviously imperative
for assessing the risk posed by such isolates.
In this report we characterize 12 highly diverged VDPVs
isolated between 1998 and 2006 from two geographically separ-
ated Israeli population with a high documented immune profiles
and address possible risk of re-emergence of disease. One or more
individuals may have continuously excreted these highly neuro-
virulent VDPVs into the environment during this interval.
Molecular analyses of these VDPVs indicate that the isolates
could be divided into two groups that evolved independently.
Isolates within each group shared a common evolutionary origin
from an ancestral Sabin2/Sabin1 recombinant strain. In one
group 9 isolates diverging along 5 separate lineages while in the
other 3 isolates diverged within a single lineage. These findings
raise serious concern about reemergence of VDPVs into the
circulating pool of neurovirulent polioviruses.
RESULTS
Presence of 12 VDPVs in sewage between 1998 and
2006
Poliovirus presence in sewage systems in Israel and the Palestinian
territories has been monitored monthly in sentinel sites since 1989.
These sewage systems include one in central Israel in the Tel Aviv
area which serves a population of 1.6 million and another serving
0.7 million out of the total population in Jerusalem and
surrounding communities (described in more detail in the
electronic supplement). In the 17 years between 1989 and 2006,
there were no VDPVs found at any sentinel sites in Israel, the
Gaza District and the West Bank other than those reported in this
manuscript that were isolated from the Tel Aviv area in central
Israel between 1998 and 2006 and from the Jerusalem area in
2006. VDPV negative sentinel sites included Haifa, Beersheba,
Rahat, Gaza district and various communities in the West Bank.
On 6 occasions between 1998 and 2004, sewage collected at the
entrance to the main treatment plant of the central Israeli sewage
system in the Tel Aviv area (Primary Site #1; Figure S1) contained
polioviruses with characteristics that differed from OPV. These
viruses grew at 40uC, were not neutralized by Sabin 1, 2, or 3
specific monoclonal antibodies and their RNA did not hybridize
with vaccine specific probes in dot blot hybridization analyses [25].
For reference, .50 samples were collected from this sentinel site
prior to the 1998 and none contained VDPVs.
After the 6
th isolate was obtained in 2004, 5 additional monthly
sampling sites were chosen at the mouths of major tributaries
within the system to increase the chance of isolating more VDPVs
and to more precisely locate the site of their entry into the sewage
system (Secondary Sites #1-A to #1-E; Figure S1). In 2005, 3
additional VDPV isolates were obtained from sewage collected at
one of these secondary sites. The specific site was located at the
mouth of a trunk line serving a population of 800.000 (Site #1-A,
Figure S1). As a consequence, this branch of the sewage system
was subdivided into sub-regions monitored at 3 new tertiary sites
(Tertiary Sites (#1-A-1 to 1-A-3, Figure S1). In 2006 two VDPVs
were isolated from one of these tertiary sites (Tertiary Site #1-A-
1). Interestingly, while this site (Site 1-A-1) represents a small
population averaging 50,000 individuals, a large part of this
population is constantly turning over since the major contributors
of sewage to this subdivision are the hotels along the Mediterra-
nean seashore.
One month prior to isolation of the 2 VDPVs from the tertiary
site in the central region of Israel, a single VDPV was isolated from
a totally unrelated sewage system. The sample containing this
isolates was a pooled sewage sample representing a major portion
(approximately 700,000 individuals) of the population of Jerusalem
and the surrounding municipalities (Site #2, Figure S1). Between
1998 when VDPV was first found in Israel in the Tel Aviv area
and the end of 2005, .105 samples were analyzed from the
Jerusalem area covered by the pooled sample and all were negative
for VDPVs.
The quality of sampling and sample processing was uniformly
high. For example, polio vaccine was isolated from 62% of sewage
samples collected between 1998 and 2002 at the primary site in
Tel Aviv (Site #1). Following introduction of enterovirus
monitoring in 2002, enterovirus was isolated from .97% of the
samples from this primary site, and from .97% of the samples
from secondary and tertiary sites. Similarly, polo vaccine was
isolated from 64% of all individual samples collected between
1998 and 2002 within the Jerusalem areas represented by the
pooled VDPV positive sample and enterovirus was isolated from
96% of the samples collected from 2002 to the end of 2005.
Genomic sequences of the 12 VDPVs have EMBL access
numbers, AJ288062, AM040035-39, AM056049-50, AM158275-
6, and AM292219-21. Access numbers for Sabin 1 and Sabin 2
sequences are V01150 and X00595, respectively. The EMBL
alignment access number for the first 9 VDPVs is DS 63108. The
names of the isolates as filed in the EMBL database have been
simplified for this manuscript (see Table S1). They have been re-
named SDs to indicate that they were Sabine derived. In addition
all SD isolates have a two digit numbers indicating the year of
isolation. In cases where more than 1 VDPV was isolated within
a given year, an additional digit indicates the order of isolation (i.e.
isolate PV2-5104-1_ISR99 (AM04003X) being the third type 2,
VDPV isolate in Israel in 1999 has been renamed SD-99-3).
Evidence for a shared evolutionary pathway for 9
VDPVs isolated between 1998 and 2005
The entire genomes of the first 5 VDPV isolates [26] were
sequenced. For the 4 subsequent VDPVs partial genomic
Neurovirulent VDPV in Sewage
PLoS ONE | www.plosone.org 2 December 2006 | Issue 1 | e69sequences were obtained that included a major portion of the
59UTR, the complete P1 region encoding all 4 structural proteins
(capsid proteins VP1, VP2, VP3, and VP4), and the non-structural
viral polymerase, 3D. A diagram of the genomic regions that were
analyzed is shown in Fig. 1. Since the VP1 sequence of all 9
isolates diverged from Sabin-2 by 8.7%–14.0% [Table S2] and
their source and evolutionary path were unknown, these VDPV
isolates will hereinafter be referred to as ambiguous aVDPVs [17].
A non-vaccine origin had previously been ruled out for the first
aVDPV, SD-98 [8], because its VP1 sequence was genetically
much closer to Sabin 2 than to any of the wild type polioviruses
found in the Middle East or elsewhere since 1980. The VP1
regions in all 8 subsequent VDPV isolates also showed the highest
degree of homology with Sabin 2 (not shown).
Determining the degree to which a group of poliovirus isolates
share common features such as genomic recombinations and
identical substitutions allows assessment of their relatedness. An
important finding in the evolutionary development of these 9
VDPVs is that they all share the same genomic recombination that
occurred in the middle of the 3D polymerase gene at positions
equivalent to nucleotides 6693 and 6705 of Sabin 2 (Acc: X00959).
Interestingly, at this point homology shifts from Sabin 2 to Sabin
1. This common recombination point is shown in an Identity Plot
generated by the NICER program (upper panel of Fig. 2). This
common recombination can be confirmed by similarity analyses
using programs such as SimPlot (see Figure S2). This common
recombination fingerprint provides strong evidence that all 9
aVDPVs evolved from a common ancestral Sabin2/Sabin1
recombinant.
Further evidence that all 9 aVDPVs were highly related comes
from the large numbers of identical substitutions observed in all 9
aVDPV sequences when comparing them to Sabin 2. Non-coding
regions and coding regions of structural and non-structural genes
may be subjected to different evolutionary pressures. Therefore
each of these regions was subdivided into 2 regions that were
analyzed separately (Fig. 1). The two segments of the 59 untrans-
lated region (59UTR) that were analyzed were a highly conserved
450 nucleotide region (R1), and a hypervariable 67 nucleotide
region [27] (R2). The next two analyzed segments consisted of
2637 nucleotides of the entire structural genomic region, P1 (R3)
and 903 nucleotides of capsid protein VP1 (R4). The final two
segments encoding non-structural genes included a 669 nucleotide
region of the viral RNA polymerase 3D gene located before the
site of recombination (R5) and a 705 nucleotide region of 3D
located after the recombination site (R6).
In regions R1 through R6, Identity Analysis using the NICER
program revealed 13, 10, 56, 21, 25 and 18 nucleotide positions,
respectively, that had identical nucleotide substitutions relative to
Sabin 2 in all 9 aVDPVs. In addition, there were 5, 2, 26, 8, 14,
and 4 nucleotide positions in regions R1 through R6, respectively,
where 8 of the 9 VDPVs had identical substitutions. The Identity
Analysis results for region R3 can be seen in the graph labeled ‘‘B’’
in the middle panel of Fig. 2 and the results for region R4 can be
seen in the graph ‘‘B.1’’ in the bottom panel of Fig. 2. Graph ‘‘B’’
shows the frequency of identical (9 of 9) and near identical (8 of 9)
substitutions. Graph ‘‘B.1’’ indicates each nucleotide position
along the viral genome where at least 1 of the 9 aVDPV different
from Sabin 2 and the per cent of all isolates with highest number
of identical substitutions at that position.
Despite a maximum inter-isolate divergence of 15.4% [Table S2],
these molecular data strongly suggest that all 9 aVDPVs evolved
from a common ancestral type2 vaccine-derived Sabin2/Sabin1
recombinantstrain.Asrecognitionofthissharedevolutionaryorigin,
these 9 aVDPVs will be referred to as Group 1 aVDPVs.
Phylogenetic analysis
Evolutionary relatedness of the 9 Group 1 aVDPVs has also been
assessed by construction of phylogenetic trees. Separate maximum
likelihood phylogenetic trees were prepared for regions R1
through R6 (Figs. 3A–F, respectively). Data was bootstrapped
100 times and only branches that appeared in .90% of the trees
formed from the 100 bootstrapped data sets were depicted. The
trees shown are true rooted trees since the ancestral sequences are
known, i.e. Sabin 2 for regions R1 to R5, and Sabin 1 for region
R6. The 9 aVDPVs group into 5 major lineages for VP1 (region
R4, Fig. 3D). Interestingly the topologies of the trees from the
other genomic regions were very similar but not completely
super-imposable (note alterations in branch positions of SD-99-2,
SD-99-4 and SD-04). Similarity in the topology of genes derived
from Sabin 1 and genes derived from Sabin 2 strongly suggests
that the recombination occurred before most of the other
mutations, probably soon after vaccination. Such intratypic
recombinations in vaccine recipients are common [10].
Estimating the time of the initiating exposure
Three different methods used to estimate the time of initial
exposure to Sabin 2 of Group 1 aVDPVs yielded 3 different
estimations for the date of initial exposure to Sabin 2: 1991–1996;
1986 and 1985–1987. All three approaches were based on rates of
nucleotide substitutions in capsid protein VP1. The first two
methods analyzed only synonymous codon substitution rates while
the third method included the overall rate of synonymous and
non-synonymous substitutions. Synonymous codon substitutions
do not alter the amino acid composition of the viral protein,
whereas, non-synonymous codons might subject progeny to
negative or positive selection. Thus the rate of appearance of
synonymous codons probably more closely represents the true rate
of nucleotide substitutions. We have used the common analytical
approach (based on synonymous codons alone) that looks at
substitutions in the 3
rd nucleotide position where most synony-
mous substitutions are found. It also excludes double substitutions
since the order of substitutions is unknown making it almost
Figure 1. Genomic fragments of type 2 VDPVs amplified by RT-PCR
for sequencing and phylogenetic analysis.
The polyprotein encoded by the Sabin 2 genome is represented by
a rectangle on the genomic RNA. The 59 UTR (partial), P1, VP1, and 3D
polymerase regions that were amplified by RT-PCR and sequenced are
represented by 4 rectangles with dark cross hatching below the
genomic RNA. They correspond to nt 183 to 747, 748 to 3384, 2482 to
3384, and 5986 to 7368, respectively, of Sabin 2 (Acc: X00595). The
downward pointing arrow indicates the start of the hypervariable
region of 59UTR. The upward-pointing arrow indicates the location of
the genetic recombination in the 3D polymerase gene. The letters R1
through R6 correspond to the separate regions used for sequence
comparisons and phylogenetic analysis as shown in Figs. 2, 3 and 4.
doi:10.1371/journal.pone.0000069.g001
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and VP1 regions.
Upper panel: An Identity Plot created by the NICER program of the nucleotide sequences of Group 1 (G1) and Group 2 (G2) aVDPVs compared with
Sabin 1 (S1) and Sabin 2 (S2) at each nucleotide position of 3D where Sabin 1 and Sabin 2 differ. The nucleotides of the query sequences are scored as
identical to Sabin 1 (light orange/light grey(B&W)), identical to Sabin 2 (dark brown/dark grey(B&W)), or different from both (grey/white(B&W)).
The upward pointing arrow (G1-X), indicating the most likely position where identity of the Group 1 sequences shifts from Sabin 2 to Sabin 1, has
been placed between positions 19 and 20 which corresponds to nucleotides 6693 and 6705 of Sabin 2 (Acc: X00595). The downward pointing arrow
(G2-X); indicating the most likely position where identity of the Group 2 sequences shifts from Sabin 2 to Sabin 1, has been placed between positions
52 and 53 which corresponds to nucleotides 6771 and 6774 of Sabin 2 (Acc: X00595).
Middle panel: An Identity Frequency plot to indicate the frequency of occurrence of nucleotide positions in P1 (region R3) of the reference sequence
(Sabin 2) where the equivalent nucleotide on at least one of the query sequences differs was created by the NICER program. The number and
frequency of identical positions (all of query sequences differ and all have the identical substitution; N/N) and near identical positions (all but one of
the query sequences have identical substitutions; N-1/N) is shown for analysis of 6 Group 1 aVDPVs isolated between 1998 and 2004 (A); the 6 Group
1 isolates in A plus the 3 Group 1 aVDPVs isolated in 2005 (B); the 6 Group 1 isolates in A plus the 3 Group 2 aVDPVs isolated in 2006 (C); and all 9
Group 1 and 3 Group 2 isolates (D) is shown. For example; in plot A there were 70 positions where 6 of 6 query sequences had identical substitutions
and this identity occurred in 12.5% of all positions where at least one of the query sequences differed from the reference sequence.
Bottom panel: An Identity Frequency Distribution plot to indicate the nucleotide position where the equivalent nucleotide on at least one of the
query sequences differs from the nucleotide in VP1 (region R4) of the reference sequence (Sabin 2) and % of query sequences that had the maximum
number of identical substitutions at each of those positions. Analysis of the 6 Group 1 aVDPV isolates plus either the 3 Group 1 aVDPVs isolated in
2005 (B.1) or the 3 Group 2 aVDPVs isolated in 2006 (C.1).
doi:10.1371/journal.pone.0000069.g002
Neurovirulent VDPV in Sewage
PLoS ONE | www.plosone.org 4 December 2006 | Issue 1 | e69impossible to determine whether the change at the 3
rd position was
synonymous or not.
Our first approach to evaluating the time of initial exposure
assumed that the aVDPV evolved at the same rate as other
polioviruses (3% 3
rd position synonymous substitutions per year)
[3,8,17,28]. A simple division of the % of synonymous substitu-
tions for each isolate by 3% indicated that initial exposure to Sabin
2 occurred sometime between 1991 and 1996. This broad range
questions the basic assumption that the annual substitution rate
was 3%.
A more rigorous approach was to extrapolate, a linear
regression of the % accumulation of 3
rd position synonymous
substitutions versus the date of isolation back to 0%. These results
(Fig. 4A) imply that initial exposure occurred in 1986 and the rate
of misincorporation was much slower than the reported rate for
other polioviruses [3,8,17,28].
The third approach involved construction of a bootstrapped,
neighbor joining phylogenetic tree rooted to Sabin 2 (Fig. 4B).
Branches of such a tree are proportional to evolutionary distance,
and conversely the entire tree is proportional to the time of evolution
along individual branches. Since the time between isolation of each
aVDPV is known, the time of evolution along each of the different
branches can be determined. The proportional time range for the
entiretreewasestimatedbydeterminingtheratiobetweenthelength
of the branches with the minimum and maximum times of evolution
and the length of the entire tree. The results indicate that first
exposure occurred between 1985–1987 and support the slower rate
of evolution indicated by the regression analysis.
Evidence that the 3 aVDPVs isolated in 2006 are
related but evolved independently from Group 1
aVDPVs
The 3 aVDPVs isolated in 2006 were subjected to the same types
of analysis as the Group 1 aVDPVs. Like Group 1 aVDPVs, they
had evolved from Sabin 2. The VP1 and P1 regions of the aVDPV
from Jerusalem were very closely related to those of the two
isolates from the central Tel Aviv region (Table S2). A simple
neighbor joining tree rooted to Sabin 2 indicated that they
belonged to a 6
th lineage (not shown). However after more
intensive analysis assisted by the NICER program, evidence
accumulated suggesting that these 3 aVDPVs had evolved
independently from the previous 9, Group 1 aVDPVs and thus
belong to a new evolutionary group which we will call
Group 2.
Firstly, Group 2 isolates recombined with Sabin 1 in the
polymerase gene, however most significantly at a point different
from those of all Group 1 aVDPVs (compare arrow G1-X between
nucleotide positions 6693 and 6705 with arrow G2-X between
nucleotide positions 6771 and 6777 in the upper panel,
Fig. 2.).
Secondly, these Group 2 isolates did not share most of the
identical (9/9) and near identical (8/9) substitutions shared by the
9, Group 1 aVDPVs. This is illustrated by the sequential
comparative identity analysis results (NICER analysis) shown in
the middle and lower panels of Fig. 2. For the middle panel, the P1
genomic regions (region R3) of the 6 aVDPVs isolated between
1998 and 2004 were compared with Sabin 2. The number of
identical (6/6) and near identical (5/6) substitutions, 70 and 46,,
respectively were used a baseline for determining whether sub-
sequent aVDPV isolates evolved from the same Sabin 2 progenitor
or from a different Sabin 2 progenitor. In the examples shown,
identical (9/9) and near identical (8/9) substitutions were
recalculated for these 6 and either the 3 related Group 1 aVDPVs
from the single lineage in 2005 or the three related Group 2
aVDPVs from the single lineage in 2006 (B and C, respectively,
middle panel, Fig. 2). The number of identical and near identical
substitutions decreased slightly to 56 and 26, respectively, when
the remaining 3, Group 1 aVDPVs were added (Graph B). In
contrast, they dropped precipitously to 14 and 9, respectively
Figure 3. Phylogenetic relationships among Type 2 aVDPVs at 6 locations along the genome.
Phylogenetic trees 3A through 3F are maximum likelihood phylogenetic trees for 6 regions distributed along the polioviral genome, two in the 59
non-coding region, 2 in the region encoding structural genes and 2 in the region encoding non-structural genes (R1–R6 in Fig. 1). The non-coding
regions analyzed are R1, the 59UTR encoding domains III to VI (Fig. 3A; nt 196 to nt 645), and R2, the 59UTR hypervariable region (Fig. 3B: nt 646 to nt
712). The regions encoding structural genes analyzed are R3, the P1 region encoding all capsid proteins (Fig. 3C; nt 748 to nt 3384), and R4, VP1
(Fig. 3D; nt 2482 to nt 3384). The regions encoding nonstructural genes are R5, the RNA polymerase gene before the recombination point (Fig. 3E;n t
5986 to nt 6690), and R6, the RNA polymerase gene after the recombination point (Fig. 3F; nt 6700 to nt 7368). Nucleotide positions are given relative
to Sabin 2 (Acc: X00595).
Trees were prepared using the dnaml maximum likelihood application of the PHYLIP program. The transition:transversion ratio was set at 10, data
was bootstrapped 100 times and the order of sequences for each bootstrap randomized 3 times. Trees A through E are rooted to Sabin 2, while tree F
is rooted to Sabin 1(Acc: V01150). Branch lengths correspond to the number of times a given branch appears among all bootstrapped trees. All
branches with bootstrap values ,90% have been collapsed. The trees were visualized using the njplot program.
doi:10.1371/journal.pone.0000069.g003
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even lower when all 12 aVDPVs were analyzed (Graph D). The
bottom panel shows the distribution along the genome within VP1
(region R4) of all nucleotide positions where at least one of the
isolates differed from Sabin 2 and the % maximum number of
identical substitutions at that location. The combinations of
isolates analyzed for Graphs B.1 and C.1 were identical to those
for Graphs B and C, respectively. The local and global distribution
of identical substitutions is clearly qualitatively very different
when results for related isolates (6 plus 3 Group 1 aVDPVs)
are compared with results for the 6 Group 1 and 3 Group 2
aVDPVs.
Thirdly, the rate of accumulation of nucleotide substitutions of
the 3 Group 2 aVDPVs is not consistent with that for the Group 1
aVDPVs if it is hypothesized that all 12 aVDPVs share a common
evolutionary path from the same progenitor Sabin 2 isolate. This is
most clearly demonstrated in the regression analysis for de-
termining the common date of initial exposure for the 9 Group 1
isolates (Fig. 4A) by the failure of the Group 2 isolates to fall even
close to the Group 1 regression line.
Characterization of genetic changes with potential
phenotypic significance
Only two nucleotide substitutions are responsible for the
phenotypic shift from the wild type-2 neurovirulent poliovirus
parental strain to the Sabin-2 attenuated vaccine strain [9]. Both
of these neurovirulence attenuation sites genotypically reverted to
wild type in all 9 Group 1 and 2 aVDPV isolates. Specifically,
nucleotide 481 in the 59UTR reverted from A to G and the ATT
codon (isoleucine at position 143) in VP1 was changed into ACT
in 8 Group 1 and 3 Group 2 aVDPV or to ACA in one Group 1
aVDPV (both ACT and ACA encode threonine).
Other sites of significance were found in viral genomic regions
encoding capsid proteins VP1, VP2 and VP3. These sites encode
amino acid sequences that are important for immune recognition.
Disease prevention is determined to a large extent by the degree in
which neutralizing antibodies against these epitopes in vaccine
strains recognize non-vaccine poliovirus. Differences in the amino
acid composition at these neutralizing antigenic sites can affect this
recognition. The positions of these epitopes for type 2 poliovirus
were based on analogy with known sites for types 1 and 3
polioviruses [8,28]. Computer generated translation of the genes
encoding these capsid proteins for the 9 Group 1 aVDPVs
indicated 12.161.5 amino acid substitutions (range 10 to 15 per
aVDPV, Table 1.) within and bordering these neutralizing
antigenic sites in all three capsid proteins. In contrast there were
5.061.0 (range 4 to 6) substitutions for Group 2 aVDPVs. This
clear difference further substantiates division of the isolates into
two independent groups.
Phenotypic reversion to neurovirulence of aVDPV
isolates
The effect of the nucleotide substitutions at both neurovirulence
attenuation sites was confirmed in a mouse model. Transgenic
mice expressing the human receptor for poliovirus were
challenged with 1.021.8610
8 PFU of Sabin 2, MEF (wild vaccine
type 2), S139C6 (a minimally diverged, highly neurovirulent type 1
vaccine strain), and aVDPV isolates SD-98, SD-99-1, SD-99-2
and SD-99-4. The Mean Health Time of 1460.0 symptom free
days [8,29] for mice challenged with the Sabin 2 vaccine control,
was reduced by MEF and S139C6 viruses to 9.661.5 and
2.860.1 days, respectively. The number of symptom free days
after challenge with 1.0610
8 PFU of SD-98, SD-99-1, SD-99-2
and SD-99-4 were 3.160.1, 7.161.6, 3.660.2 and 3.160.1,
respectively. Increasing the challenge dose of SD-98 to 2.8610
8
PFU reduced the number of symptom free days to 2.660.3. Thus
all Group 1 aVDPVs tested were extremely neurovirulent in the
animal model.
Assessment of age-related immunity to aVDPV
isolates
To determine whether predicted amino acid substitutions in
neutralizing antigenic sites altered the aVDPVs antigenically,
thereby affecting the population immunity against them, we
compared antibody titers from standard neutralization assays.
Four aVDPV isolates, SD-98, SD-99-1, SD-04, and SD-05-1, one
from each year and representing 4 of the 5 Group 1 lineages, were
tested in parallel with Sabin-2 and MEF using sera obtained from
cohorts of different ages (described in Table 2). A more limited
survey was carried out comparing the titers against MEF and
representative Group 1 (SD-98) and Group 2 (SD-06-1 and SD-
06-2) aVDPVs in cohorts F, G, and H (Table 2).
Figure 4. Estimation of the date of initial exposure to Sabin-2.
Fig. 4.A. is a method for estimating of the date of initial exposure based
on regression analysis of the accumulation of the % of 3
rd position
synonymous substitutions from all codons with single nucleotide
substitutions in VP1 (region R4 in Fig. 3D). The date of initial exposure
to Sabin 2 was determined by extrapolation backwards to 0%
substitutions. (r
2=0.886). Group 1 isolates are represented by open
circles while Group 2 Isolates are represented by open triangles.
Fig. 4.B is a rooted, neighbor-joining, phylogenetic tree of the same
region, region, R4, analyzed in Figs. 3D and 4.A. Unlike Fig. 4.A,
substitutions in all three codon positions were taken into account. The
tree was prepared with ClustalX. Data was bootstrapped 1000 times.
The numbers on the branches are the bootstrap values. The tree was
visualized using the njplot program. Branch lengths correspond to
genetic distances. Since dates of isolation are know, branch lengths
were converted to time. The time for the distance between Sabin 2 and
the first branch was calculated proportionally to the minimum and
maximum branch ‘‘times’’ between different pairs of aVDPVs.
doi:10.1371/journal.pone.0000069.g004
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against the vaccine strains in age-grouped cohorts A through E
(Table 2). The geometric mean titers (GMT) for antibodies
neutralizing Sabin-2 and MEF, calculated as described [30],
declined .10 fold as the age of the cohorts increased from
15 months to 18 years and then stabilized for the next 35 years
(p,0.05, Wilcoxon signed rank test for unpaired data) (Fig. 5).
The GMT for adults was still protective and the age-related
decrease was consistent with previous studies [30].
The next step was to compare the GMT against vaccine strains
and representative aVDPVs. At each age group, the GMT against
Group 1 aVDPV strains SD-98, SD-99-1 and SD-04 was
significantly lower than the GMT of antibodies to vaccine strains
(Fig. 5., p,0.005, Wilcoxon signed rank test for paired data).
While at some ages, the GMT for one VDPV was significantly
different from the others (p,0.05), there was no aVDPV that was
consistently different at all time points. Moreover, within the 20–
50 year old cohort there were 6 individuals who had neutralizing
antibody titers below 1:8 against SD-98, 3 against SD-04 and 1
against both SD-99 and SD-04. In contrast, these 10 individuals
were still protected against both vaccine strains. This group had
GMTs against Sabin 2 and MEF of 69 and 53, respectively, and
all individuals had protective titers (i.e. above 1:8). Thus 10/150
(7%) individuals .21 years old who had protective neutralizing
antibody titers against Sabin 2 and MEF had titers below the
minimum protective level of 1:8 for at least one or more of
the VDPV strains. The GMT against Group 1 isolate SD-05-1
was significantly lower than that against MEF (Table 3) in
cohort F.
GMT against MEF, Group 1 isolate SD-98, and Group 2
aVDPVs SD-06-1 and SD-06-02, were tested in cohorts G and H.
Consistent with previous findings, the GMTs for Group 1 SD-98
were significantly lower (p,0.05) then against MEF (Table 3). The
GMTs for Group 2 isolates fell between those for MEF and SD-
98, however with the exception of SD-06-1 in cohort G, they were
not significantly different from MEF.
Table 2. Age-grouped cohorts used for determining GMT to type 2 poliovirus strains.
..................................................................................................................................................
Cohort Age in years Date collected
a Number of Samples Vaccination status
A 1.25 2000; SS 28 Intercalated 36eIPV plus 36OPV
B 6 1998; SS 22 Intercalated 36eIPV plus 36OPV; OPV booster at 6 yrs
C 14 2004; SS 20 Intercalated 36eIPV plus 36OPV; OPV booster at 6 yrs
D 18 1997; ICDC 78 Status unknown; convenient sample
E 21–50 2003; ICDC 150 (5 per year) Status unknown; convenient sample
F 20–24 2005; ICDC 15 (3 per year) Status unknown; convenient sample
G 11–12 2003; SS 12 Intercalated 36eIPV plus 36OPV; OPV booster at 6 yrs
H 20–30 2004: ICDC 12 Status unknown; convenient sample
aYear serum collected; SS (Standard sero-survey; vaccine status available for all members of cohort) or ICDC (convenient samples are random samples from the Israel
Center for Disease Control serum bank)
bThe basic intercalated vaccination program in Israel between 1990 and 2005 consisted of a dose of enhanced inactivated polio vaccine (eIPV) at 2 months, combined


























































The amino sequences of Sabin 2 adjacent to and within neutralizing antigenic sites inferred as previously described [5] is presented on the top line. The numbers above
the amino acids refer to the amino acid positions within each capsid protein. Only substituted positions are shown for aVDPVs and MEF. # indicates the sum of all
amino acid substitutions at all neutralizing antigenic sites followed by the mean6standard deviation for Group 1 and Group 2 aVDPVs.
doi:10.1371/journal.pone.0000069.t001
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The efficacy of the Israeli vaccination program has been
documented, showing that neutralizing antibody titers for all age
groups were .1:8 against all three OPV and IPV serotypes in
.95% of the population [2,30]. Protective titers drop .10 fold by
age 18. The population benefits from this high immunity and has
not endured any poliomyelitis outbreaks since 1989 despite
numerous wild poliovirus importations into the Gaza district
[4,23]. These incursions were detected in the absence of paralytic
disease by environmental surveillance of sewage samples. The
environmental surveillance also detected 9 related and highly
diverged VDPVs that have been isolated from sewage over the 8-
year period, 1998–2005. Six were from a site located at the
entrance of the main sewage treatment facility serving 1.6 million
people in central Israel where no VDPV were detected in .50
monthly samplings before 1998 or .15 after 2004. Another three
VDPVs were isolated from a secondary site located upstream on
a trunk line serving 800,000 people. An additional 3 highly
diverged VDPV were isolated in 2006, 1 from a separate
geographical location, the Jerusalem area, and 2 from one of the
trunk lines leading into the secondary site where the 3 isolates were
obtained in 2005. All isolates were clearly VDPV since molecular
evidence showed closer homology to Sabin 2 than to any wild type
2 polioviruses anywhere since 1980 [8].
It is difficult to determine the number of infected individuals
from sewage [24] and the one or more excretors of these VDPVs
remain unidentified. The evolutionary path of these isolates is
unknown for which reason they have been designated ambiguous
aVDPVs [17]. The lack of detection in most 1998–2005 samples
probably relates to several factors: the limits of detection [24], the
intermittent presence of the excretor(s) in the surveillance area,
and/or the percent of stool samples containing poliovirus from
known iVDPV sources [28].
A unique recombination marker and a high number of identical
nucleotide substitutions indicate that all 9 aVDPVs isolated
between 1998 and 2005 evolved from a common Sabin2/Sabin1
recombinant ancestral strain despite #15% inter-isolate diver-
gence. This high divergence (Supplement Table 1) and the short
time between isolations appear to rule out direct sequential
evolution and favor parallel development along at least 5 separate
lineages. Divergence commenced well before the first isolates were
identified. However, the divergence of the closely related isolates
in two lineages appears to have occurred more recently, e.g., SD-
99-2 and SD-99–4 in one lineage and the three 2005 isolates in
another. For this discussion we designate these 9 aVDPV as Group
1 aVDPVs to indicate that they evolved in parallel, concurrently
from a common ancestor. The 3 aVDPVs isolated in 2006 differ
from Group 1 isolates by their different recombination pattern,
low number of shared identical recombinations, and different
apparent date for commencement of evolution, as well as by
a different pattern of amino acid substitutions in neutralizing
antigenic sites. For this discussion we designate these 3 aVDPVs as
Group 2 aVDPVs to indicate that they evolved in parallel, and
concurrently but from a different ancestral Sabin 2 isolate than
Group 1 aVDPVs.
High sequence diversity by evolution from a common ancestor
implies a long chain of replication in one or more human hosts.
Each of three events had to have occurred in a single individual
although not necessarily the same one: initial exposure to trivalent
OPV, intertypic recombination between Sabin 2 and Sabin1 in
the polymerase gene and the identical nucleotide substitutions
throughout the genome.
Characterization of the early stages of VDPV emergence
[11,31,32] and the late stages in evolution of iVDPV and cVDPV
(Reviewed in [17,18]) have provided the following guidelines for
distinguishing between evolution in a single individual and
evolution during a long chain of host-to-host transmission.
iVDPVs are characterized by co-evolution of many lineages in
a single immune compromised host. They presumably colonize
different areas of the gut [28], are excreted intermittently, have
numerous amino acid substitutions in neutralizing antigenic sites
and if recombine, intratypically recombine with polioviruses [28]
but not with clade C enteroviruses. In contrast, cVDPVs are
transmitted from one naive host to another and usually have few
distinct lineages and significantly fewer amino acid substitutions in
antigenic sites. cVDPVs readily recombine with polio and non-
polio enteroviruses, probably as soon as they start circulating [32].
The Israeli Group 1, poliovirus type 2 aVDPVs were character-
ized by multiple lineages, numerous amino acid substitutions in
neutralizing antigenic sites, a single intratypic polymerase gene
recombination with type1 poliovaccine, no recombinations with
clade C non-polio enteroviruses and intermittent isolation
patterns. These characteristics are more consistent with iVDPVs.
Phylogenetic trees were prepared from different genomic regions
Figure 5. Geometric mean titers (GMT) of neutralizing antibodies
against Type 2 strains by age group.
The GMT for each strain was calculated for each age group after data
was normalized by comparison to titers from a standard pool of 20
positive sera included in each analysis as described in Materials and
Methods. The cohort (see Table 2) for which each GMT point was
determined is shown at the top of the figure. The symbols for each
isolate are in Fig. 5B.
Fig. 5.A represents GMT of neutralizing antibodies to poliovirus in sera
from cohorts aged 15 months to 15 years in which the complete
immunization history of all individuals was documented.
Fig. 5.B represents the GMT in sera from cohorts aged 18 years to
50 years from convenient samples obtained from the serum banks of
the Israel Center for Disease Control (ICDC).
doi:10.1371/journal.pone.0000069.g005
Table 3. Geometric mean titers (GMT) of neutralizing
antibodies against Type 2 strains by age group.
......................................................................
COHORT MEF-2 SD-98 SD-05-1 SD-06-1 SD-06-2
F 268 n.d. 61* n.d. n.d.
G 512 143* n.d. 406 323*
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deficient patient[28]. Minor incongruencies of tree branching
were used to suggest intratypic recombination between those
iVDPV isolates. Recombination can only occur when both isolates
replicate within the same infected cell in a single individual. Thus
similar incongruence in branching patterns observed between
regions for Israeli aVDPVs might also indicate intratypic
recombinations between lineages in a single host. If so, this would
indicate simultaneous presence in a single host and strengthen the
likelihood that isolates are iVDPV. The apparent time interval
between initiation of evolution of the aVDPVs and the Sabin 2/
Sabin 1 recombination event might be explained by re-exposure of
a chronically infected infant with trivalent OPV at age 5 to 6 or by
contact with immunized siblings. The location at which the initial
trivalent OPV exposure occurred for Group 1 and Group 2 is
unknown and may or may not have occurred in Israel. Both
Group 1 and Group 2 aVDPVs could have circulated in sub-
populations with low vaccine coverage, although such pockets
have not yet been identified (see example [33]). Additionally, even
highly immunized healthy children can potentially support
poliovirus circulation: more than 60% of #15 month old infants
immunized with 3 IPV and 3 OPV doses and with an excellent
humoral immune profile still excreted high poliovirus titers some
for up to 3 weeks following re-challenge with OPV [T. Swartz, et
al. unpublished].
This novel isolation of several highly related aVDPVs over long
time intervals suggests that our advanced surveillance techniques
can repeatedly detect iVDPV in a community of 1.6 million
individuals. Furthermore, if these Group 1 isolates are iVDPV
they represent a significantly longer chronic infection in the
absence of poliomyelitis and have a much higher genetic
divergence of co-infecting lineages than reported for all identified
patients, but one [17]. Furthermore the sequential isolation of the
Group 2 aVDPVs in 2 separate geographical locations indicate
that when a unified widespread surveillance program has been
consistently used, virus circulation or movement of infected
individuals between different large populations can be followed.
Recently introduced environmental surveillance programs in
South Africa [34] Estonia[35], Slovakia [36], Japan [31] and
Russia [37] also yielded aVDPVs. Thus we propose that similar
long-term studies should be undertaken worldwide to assess how
frequently VDPVs are present in the environment and the
potential global risks posed by aVDPVs and iVDPVs. Such
assessments are essential before discontinuation of vaccination as
proposed in the Global Poliomyelitis Eradication Initiative.
In our study, neutralizing antibody titers against the Group 1
aVDPVs were $3.3 fold lower compared to vaccine strains
[Fig. 5]. These titers dropped below protective levels in 7% of
immunized adults. Accumulation of adults with waned immunity
may be the equivalent of accumulation of naı ¨ve infants when polio
vaccination is interrupted[20]. Significantly, poliomyelitis oc-
curred in individuals above the age of 15 who had previously
received at least 3 doses of OPV during the last poliovirus
outbreak in Israel which occurred in 1988 [38]. The WHO
recommends investigating the cause of all cases of acute flaccid
paralysis (AFP) independently of age, but only uses the rate of
those under 15 years old for monitoring quality of AFP
surveillance. Thus, in practice, identification of virus in stools of
individuals with AFP.15 years old is inadequately investigated.
We therefore recommend that all cases of adult AFP be fully
evaluated in highly immunized populations.
cVDPV poliomyelitis outbreaks have occurred in communities
where the expected survival times for immunodeficient individuals
was short and the number of unprotected individuals high[39].
The relative risk for host-to-host transmission of disease in
a population with high immunity is low but could occur within
pockets of non-immunized individuals or between individuals with
waned immunity. Determining the time of initial exposure to
vaccine from a cluster of related aVDPVs may allow assessment of
the relative risk of introduction of the aVDPV into external
communities not as well covered by vaccination. For example,
1988 is a pivotal year for determining risks for re-emergence of
poliomyelitis based on age of the infected individual(s) assuming
that the initial exposure and evolution of Group 1 aVDPVs
occurred in Israel. The initial exposure to Sabin 2 for Group 1
isolates occurred between 1985 and 1993 depending on the
method used to calculate this date. Many factors interfere with
more accurate approximation of starting dates for evolution and
preclude use of elaborate correction algorithms [28] (discussed in
the supplement). In Israel, most individuals #40 years old were
vaccinated with OPV in 1988 as part of containment of the last
wild type poliomyelitis outbreak [38]. In 1988, evolution of VDPV
may have commenced in anyone #40. However, after 1988,
exposure would most likely have occurred in children ,8 year
olds. This cohort has now entered the age of Israeli youth who
travel abroad under hygienically compromised conditions in
tropical areas with under-immunized populations. The sudden
appearance of highly diverged Group 2 aVDPVs in more than 1
geographical region within a very short time resembles the sudden
appearance of wild type polio into Israel and the Gaza district [4].
Thus by analogy, the Group 2 aVDPV’s more likely represent
introduction(s) rather than local circulation. Isolation of highly
diverged Group 2 aVDPVs in sewage from a trunk line mainly
serving hotels along the Mediterranean in the Tel Aviv area one
month after finding a related isolate in the Jerusalem might point
to a tourist or tourists as the vector. If true, this justifies our
concern about the potential for global spread of aVDPVs like
those in Group 1 by youthful tourists visiting regions of the world
with sub-optimal vaccine coverage.
In conclusion, aVPDVs potentially circulate or are excreted for
extended durations even in very intensively OPV vaccinated
populations with high documented immunities. Taken together
with the inability to cure chronically infected individuals [40] plans
for cessation of poliovirus vaccination after eradication of wildtype
poliomyelitis must be carefully reassessed. In fact vaccination with
IPV may have to be continued until all individuals infected with
VDPV cease excreting virus. Finally supplementary environmental
sampling is a powerful surveillance tool for detecting poliovirus




Type 1, 2, and 3 inactivated poliovaccine [PV1/Mahoney/
USA41, PV2/MEF/EGY42, and PV3/Saukett/USA] and OPV
[PV1/LSc 2ab, PV2/P712 ch 2ab, and PV3/Leon 12 a1b]
reference strains and a minimally diverged, highly neurovirulent
Sabin-1 positive neurovirulence control strain S139C6 [29]were
obtained from Radu Crainic, Institute Pasteur, Paris, France.
The sewage systems
The study was performed on sewage collected prior to entry into
a treatment plant of central Israel that processes 120 million cubic
meters of raw sewage per year and from sewage from the
Jerusalem area prior to treatment by 2 plants which process 35
million cubic meters of raw sewage per year. The central Israel
system serves approximately 1.6 million residents of diverse socio-
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documented and undocumented migrant workers. The portion of
the Jerusalem area described here services 700,000 residents with
a background similar to that of Tel Aviv area residents. Central
Israeli communities serviced by the central Israel treatment plant
in 1998 and 2005 and sampling sites are shown in Figure S1.
Isolation of polioviruses from sewage samples
Composite sewage samples of one liter generated by combining
aliquots obtained automatically over a 24 hr interval were
harvested each month from most Israeli sites and treated as
detailed in the supplement. Treated samples were applied onto
L20B cells. Grab samples collected during 3 hours of peak use
were harvested from the Jerusalem area and a few other sentinel
sites. The cell monolayers were overlaid with 1% agar and the
plaques that formed were isolated for further processing as detailed
in a supplement.
The majority (.98%) of the polioviruses isolated from sewage
surveillance since 1989 have been OPVs excreted by recently
immunized individuals or contacts. Imported wild poliovirus
isolates were found sporadically in the Gaza District between
1990–2002 [4,23] , L. M. Shulman et al, unpublished.], and in
Israel in 1995 [4,23] . This report focuses on the 9 highly diverged
type 2 VDPV that were obtained from central Israel between 1998
and 2005 [8] [26]. For convenience all VDPV isolate names have
been shortened to ‘‘SD’’ for Sabin-derived, a two digit number
indicating the year of isolation, and another digit indicating the
order of isolation with in a year if there were more than one isolate
(i.e. pv2-5104-1_isr99 being the third isolate in 1999 has been
renamed SD-99-3).
Intratypic differentiation, the process for determining whether
a particular poliovirus isolate is vaccine-like (Sabin-like) or non-
vaccine-like (non-Sabin-like) is described in the supplement.
Sequence analyses
Sequence analyses were performed as described in detail in the
supplement. The location of genomic fragments that were
amplified by RT-PCR and sequenced for phylogenetic analysis
is shown in Fig. 1.
Phylogenetic analysis
Maximum likelihood phylogenetic trees representing different
genomic regions were prepared using the Dnaml application of
PHYLIP (J Felsenstein, Depart of Genetics, University of
Washington, http://evolution.genetics.washington.edu/phylip/
getme.html) . Prior to analysis, data was bootstrapped100 times
and trees generated by randomizing sequence order 3x per
bootstrap. Bootstrapping is a statistical method of resampling
sequence data to estimate error and evaluate the reliability of
a phylogenetic tree.
A neighbor joining phylogenetic tree was constructed using the
ClustalX [41] program with sequence data bootstrapped 1000
times and visualized using njplot (M. Gouy, Laboratoire de
Biometrie et Biologie Evolutive, U. Lyon, CNRS, France, URL
http://pbiol.univlyon1.fr/software/njplot.html).
Since the sequences of the VDPVs are Sabin-derived, it was
possible to root the trees to the corresponding Sabin sequences.
The frequencies of identical substitutions relative to OPV
references and identity analysis of regions containing recombina-
tions were determined using the NICER program (L. Shulman L
and J. Prilusky, Israel, URL http://bioportal.weizmann.ac.il/
nicer/). Similarity plots in the supplement were obtained by the
SimPlot program [42].
Geometric Mean Titers (GMT) to type 2 polioviruses
Sera from 8 anonymous Israeli cohorts 15 months to 50 years of
age were obtained from district health offices as part of the Health
Ministry annual sero-survey program or from the serum bank of
the Israel Center for Disease Control (ICDC). The number of
samples in each cohort, the year the samples were obtained and
the vaccine status for the members of each cohort are summarized
in Table 2. Titers of antibodies in serum that neutralized 100
TCID50 of Sabin 2, MEF, SD-98 and isolates SD-99-1, and SD-04
were determined by a micro-neutralization assay [30] and
normalized to a pool of 20 positive sera in each test run.
Neutralizing antibody titers against MEF, SD-98, SD-06-1 and
SD-06-2 were determined for additional cohorts. Titers below or
above starting and ending dilutions were assigned values of 1/2
the lowest or twice the highest dilution respectively, for GMT
calculation. Significance of titer differences between different type
2 strains within each cohort and for the same strain between
different cohorts, respectively was calculated using the Wilcoxon
signed rank tests for paired data and unpaired data.
Neurovirulence testing in transgenic mice
The magnitude of neurovirulence was determined in PVR-Tg21
transgenic mice [8,29] (provided by A. Nomoto and T. Nomura).
Five male and five female mice per poliovirus isolate were
challenged i.p. with 0.3321610
8 PFU and monitored daily for
paresis, paralysis, or death over a 14 day interval. The Mean
Health Time, defined as the mean number of days before
appearance of clinical symptoms, was assayed.
Nucleotide sequence accession numbers
aVDPV sequences have EMBL access numbers, AJ288062,
AM040035 -39, AM056049-50, AM158275-6, and AM292219-
21, while those for Sabin 1 and Sabin 2 are V01150 and X00595,
respectively. The EMBL alignment access number is DS 63108.
SUPPORTING INFORMATION
Supplement S1 Electronic Supplement to this paper.
Found at: doi:10.1371/journal.pone.0000069.s001 (7.76 MB
DOC)
Figure S1 Communities serviced by the sewage system in central
Israel. he area within the rectangle on the map of Israel (insert)
which represents the greater Tel Aviv area and major surrounding
areas in central Israel has been enlarged to show the areas serviced
by the sewage system in 1998 (grey) and those added by 2004
(hashed lines). The Primary Surveillance Site (Site #1), located
immediately before entry of sewage into the main treatment plant,
services approximately 1.6 million individuals and has been
sampled monthly since 1988. Five Secondary Surveillance Sites at
the mouth of major trunk lines located upstream from the primary
site (indicated by the smaller numbered circles) were added to try
and localize the source or sources of the VDPV. They also
increase the chances for isolating VDPVs by decreasing the
distance from the source (i.e., decreased physical factors re-
sponsible for loss of detection and decrease the amount by which
the excreted virus is diluted by the sewage). Secondary Sites #1-A
through 1-E serve 800,000, 117,000, 238,600, 221,000, and
100,000 individuals, respectively. Tertiary Site #1-A-1 serves
50,000 residents along the seashore. Hotels are the major source of
the sewage for this site. Highly-diverged type 2 VDPV isolates SD-
98, SD-99-1, SD-99-2, SD-99-3, SD-99-4 and SD-04 were isolated
from Primary Site #1. SD-05-1, SD-05-2 and SD-05-3 were
isolated from Secondary Site #1-A. SD-06-1 was isolated form
Neurovirulent VDPV in Sewage
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Tertiary Site #1-A-1.
Found at: doi:10.1371/journal.pone.0000069.s002 (0.05 MB
PDF)
Figure S2 A Similarity Plot for the recombination site in the 3D
polymerase genes of aVDPVs.The 3D polymerase gene sequences
(includes all of regions R5 and R6 and the linker in between ;
Manuscript Fig. 1) of Sabin-1, Sabin-2 and 7 VDPV were aligned
using ClustalX. A plot of nucleotide similarity between the 3D
polymerase gene of the first aVDPV to be isolated, SD-98, and the
subsequent 6 aVDPVs and Sabin 1 and Sabin 2 strains was
generated by the SimPlot program using a sliding window of 300
bp in steps of 30 nt with JC correction model for nucleotide
substitution. The first nucleotide in the alignment corresponds to
nt 5940 of Sabin 2 (Acc: X00595). Dark black trace = Sabin 1,
light grey trace = Sabin 2, and the VDPV are traces with broken
lines. The crossover point in the SimPlot between similarity to
Sabin 2 and similarity to Sabin 1 corresponds to positions 18 and
19 in the IdentityPlot shown in Fig. 2 of the manuscript.
Found at: doi:10.1371/journal.pone.0000069.s003 (0.04 MB
PDF)
Table S1 Description of the type 2 VDPV isolated from sewage
between 1998 and 2006.
Found at: doi:10.1371/journal.pone.0000069.s004 (0.03 MB
DOC)
Table S2 Pair-wise nucleotide homology among aVDPVs and
Sabin 2.
Found at: doi:10.1371/journal.pone.0000069.s005 (0.18 MB
DOC)
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